Many Perceive Lack of Choice in Receipt of RAI for Thyroid Cancer
Thyroid cancer patients who perceive no choice about radioactive iodine report lower decision satisfaction.
Endocrine Cancer
Fragmentation Pattern of Cell-Free DNA Can Reveal Cancer, Even at Early Stages
Machine learning algorithm detected 7 types of cancer in liquid biopsy and identified tissue of disease origin.
Solving the Obesity Paradox in Oncology
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis.
Pediatric Thyroid Cancer Rates Are Rising, but Some Experts Doubt the Significance
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
Once-Weekly Exenatide Treatment Does Not Increase Risk for Medullary Thyroid Carcinoma
Treatment with once-weekly exenatide 2 mg does not increase serum calcitonin concentrations or the risk for medullary thyroid carcinoma.
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
Cumulative Risk for Thyroid Cancer After Initial Benign Thyroid Biopsy
Patients who initially received negative thyroid biopsy results might face higher cumulative risk of developing thyroid cancer than that projected in previous literature.
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
Next post in General Oncology
